Literature DB >> 11825573

HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread.

Nathalie Sol-Foulon1, Arnaud Moris, Cinzia Nobile, Claire Boccaccio, Anneke Engering, Jean-Pierre Abastado, Jean-Michel Heard, Yvette van Kooyk, Olivier Schwartz.   

Abstract

DC-SIGN, a dendritic cell (DC)-specific lectin, mediates clustering of DCs with T lymphocytes, a crucial event in the initiation of immune responses. DC-SIGN also binds HIV envelope glycoproteins, allowing efficient virus capture by DCs. We show here that DC-SIGN surface levels are upregulated in HIV-1-infected DCs. This process is caused by the viral protein Nef, which acts by inhibiting DC-SIGN endocytosis. Upregulation of DC-SIGN at the cell surface dramatically increases clustering of DCs with T lymphocytes and HIV-1 transmission. These results provide new insights into how HIV-1 spreads from DCs to T lymphocytes and manipulates immune responses. They help explain how Nef may act as a virulence factor in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825573     DOI: 10.1016/s1074-7613(02)00260-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  65 in total

1.  Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Rebekah I Fleis; Chris G Przybycin; Kathleen L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

3.  Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

Authors:  Cinzia Nobile; Arnaud Moris; Françoise Porrot; Nathalie Sol-Foulon; Olivier Schwartz
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 4.  DC-SIGN: binding receptor for HCV?

Authors:  Zhi-Hua Feng; Quan-Chu Wang; Qing-He Nie; Zhan-Sheng Jia; Yong-Xin Zhou
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

5.  HIV-1 Nef binds a subpopulation of MHC-I throughout its trafficking itinerary and down-regulates MHC-I by perturbing both anterograde and retrograde trafficking.

Authors:  Ling Yi; Tilman Rosales; Jeremy J Rose; Bhabadeb Chowdhury; Bhabhadeb Chaudhury; Jay R Knutson; Sundararajan Venkatesan
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

Review 6.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

7.  Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.

Authors:  Biswanath Majumder; Michelle L Janket; Elizabeth A Schafer; Keri Schaubert; Xiao-Li Huang; June Kan-Mitchell; Charles R Rinaldo; Velpandi Ayyavoo
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.

Authors:  Pierre-Emmanuel Ceccaldi; Frédéric Delebecque; Marie-Christine Prevost; Arnaud Moris; Jean-Pierre Abastado; Antoine Gessain; Olivier Schwartz; Simona Ozden
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

9.  Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells.

Authors:  Minoru Tobiume; Janet E Lineberger; Christopher A Lundquist; Michael D Miller; Christopher Aiken
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha.

Authors:  Biswanath Majumder; Narasimhan J Venkatachari; Elizabeth A Schafer; Michelle L Janket; Velpandi Ayyavoo
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.